CONTEXT: Ten years after the use of alpha interferon in @entity2212 ( @entity2212 ) @entity1778 treatment, we review this treatment. OBJECTIVE: We propose through this study to evaluate the therapeutic answer of the @entity1 reached of @entity2212 in chronic phase and to study its impact on survival. MATERIAL AND METHODS: To be done we carried out a descriptive and analytical retrospective study concerning 40 @entity1 carrying @entity1860 . RESULTS: The average age was 39.05 years and ratio sex was 0.9. 60% of the @entity1 profited from the arm @entity1862 + Interferon alpha + @entity2592 and 40% from @entity1862 + @entity14584 . The complete haematological answer was observed in 85.5%. The cytogenetic answer was documented only for two cases, and it acted of complete answer. On the evolutionary level, it was noted 27.5% of deaths related to a blastic transformation. The side effects were marked by occurred of @entity1665 , @entity12949 . The median of survival observed was 68.233 months or 5.68 years. The age, socioeconomic level, delay of treatment started, therapeutic protocol, length and regularity of treatment influenced the therapeutic response. CONCLUSION: Many factors influence the treatment response.

[Therapeutic impact of alpha interferon in chronic XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity2212 :: ('MESH:D015466', 'Disease') :: ['chronic myelogenous', 'CML'] @entity12949 :: ('MESH:C536395', 'Disease') :: ['herpes and the gripal syndrome'] @entity1862 :: ('MESH:D006918', 'Chemical') :: ['Hydroxyurea'] @entity14584 :: ('MESH:D007372', 'Chemical') :: ['Interferon'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['Cytosine Arabinoside'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukaemia'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['Chronic Myelogenous Leukaemia']
@entity1778 :: (MESH:D007938,Disease) :: ['myelogenous leukaemia']
